ATE347698T1 - Verfahren zum nachweis von alzheimer-krankheit - Google Patents
Verfahren zum nachweis von alzheimer-krankheitInfo
- Publication number
- ATE347698T1 ATE347698T1 AT02704967T AT02704967T ATE347698T1 AT E347698 T1 ATE347698 T1 AT E347698T1 AT 02704967 T AT02704967 T AT 02704967T AT 02704967 T AT02704967 T AT 02704967T AT E347698 T1 ATE347698 T1 AT E347698T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- alzheimer
- detecting alzheimer
- detecting
- diagnostic
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/99—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0106051.6A GB0106051D0 (en) | 2001-03-12 | 2001-03-12 | Diagnostic screens for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE347698T1 true ATE347698T1 (de) | 2006-12-15 |
Family
ID=9910482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02704967T ATE347698T1 (de) | 2001-03-12 | 2002-03-12 | Verfahren zum nachweis von alzheimer-krankheit |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040132113A1 (de) |
| EP (2) | EP1370870B9 (de) |
| JP (3) | JP4430306B2 (de) |
| AT (1) | ATE347698T1 (de) |
| AU (1) | AU2002238766A1 (de) |
| DE (1) | DE60216570T2 (de) |
| ES (1) | ES2272673T3 (de) |
| GB (1) | GB0106051D0 (de) |
| WO (1) | WO2002073212A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117645D0 (en) | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
| GB0311835D0 (en) | 2003-05-22 | 2003-06-25 | Isis Innovation | Susceptibility gene for alzheimer's disease |
| ES2330465T3 (es) * | 2006-02-03 | 2009-12-10 | Mtm Laboratories Ag | Procedimiento para realizar un inmunoensayo desnaturalizante. |
| WO2010112034A2 (en) * | 2009-04-02 | 2010-10-07 | Aarhus Universitet | Compositions and methods for treatment and diagnosis of synucleinopathies |
| GB0912394D0 (en) | 2009-07-16 | 2009-08-26 | Univ Birmingham | Screening methods |
| GB201112246D0 (en) * | 2011-07-15 | 2011-08-31 | Univ Birmingham | Diagnosis of alzheimer's disease |
| GB201212334D0 (en) | 2012-07-11 | 2012-08-22 | Warwick The | Therapeutic targets for alzheimers disease |
| CN103808917B (zh) * | 2014-03-16 | 2015-11-04 | 国家烟草质量监督检验中心 | 一种电子烟烟液细胞增殖毒性评价方法 |
| CN103808919B (zh) * | 2014-03-16 | 2015-11-18 | 国家烟草质量监督检验中心 | 一种基于溴脱氧尿嘧啶核苷掺入的卷烟烟气增殖毒性评价方法 |
| WO2019113277A1 (en) * | 2017-12-08 | 2019-06-13 | NeuroDiagnostics LLC | Diagnosing disease via gene expression profile in synchronized cells |
| KR102478811B1 (ko) | 2020-08-21 | 2022-12-16 | 재단법인대구경북과학기술원 | 멀티플렉스 ｐｃｒ 플랫폼 기반의 알츠하이머 질환 진단을 위한 신규한 마커 조성물 및 이의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994000095A2 (en) * | 1992-06-24 | 1994-01-06 | Cortex Pharmaceuticals, Inc. | Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity |
| US5773219A (en) * | 1992-10-06 | 1998-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Process for detecting Alzheimer disease using cultured cells |
| US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
| AU2541497A (en) * | 1996-04-04 | 1997-10-29 | Institute Of Genomic Research, The | Variant presenilin-2 genes |
| US6342350B1 (en) * | 1997-09-05 | 2002-01-29 | The General Hospital Corporation | Alpha-2-macroglobulin diagnostic test |
| AU6265600A (en) * | 1999-06-22 | 2001-01-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method for detection of early-onset alzheimer's disease |
-
2001
- 2001-03-12 GB GBGB0106051.6A patent/GB0106051D0/en not_active Ceased
-
2002
- 2002-03-12 EP EP02704967A patent/EP1370870B9/de not_active Expired - Lifetime
- 2002-03-12 ES ES02704967T patent/ES2272673T3/es not_active Expired - Lifetime
- 2002-03-12 JP JP2002572422A patent/JP4430306B2/ja not_active Expired - Fee Related
- 2002-03-12 AT AT02704967T patent/ATE347698T1/de not_active IP Right Cessation
- 2002-03-12 DE DE60216570T patent/DE60216570T2/de not_active Expired - Lifetime
- 2002-03-12 EP EP06014441.7A patent/EP1724588B1/de not_active Expired - Lifetime
- 2002-03-12 WO PCT/GB2002/001137 patent/WO2002073212A2/en not_active Ceased
- 2002-03-12 AU AU2002238766A patent/AU2002238766A1/en not_active Abandoned
-
2003
- 2003-09-10 US US10/659,578 patent/US20040132113A1/en not_active Abandoned
-
2008
- 2008-05-29 JP JP2008141226A patent/JP4541429B2/ja not_active Expired - Lifetime
-
2010
- 2010-03-04 JP JP2010047861A patent/JP2010166922A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002073212A2 (en) | 2002-09-19 |
| EP1724588B1 (de) | 2017-05-03 |
| EP1370870A2 (de) | 2003-12-17 |
| JP4430306B2 (ja) | 2010-03-10 |
| JP4541429B2 (ja) | 2010-09-08 |
| WO2002073212A3 (en) | 2003-05-22 |
| DE60216570T2 (de) | 2007-04-05 |
| US20040132113A1 (en) | 2004-07-08 |
| ES2272673T3 (es) | 2007-05-01 |
| AU2002238766A1 (en) | 2002-09-24 |
| EP1370870B1 (de) | 2006-12-06 |
| DE60216570D1 (de) | 2007-01-18 |
| GB0106051D0 (en) | 2001-05-02 |
| EP1724588A3 (de) | 2007-09-05 |
| EP1370870B9 (de) | 2009-12-02 |
| JP2004531244A (ja) | 2004-10-14 |
| JP2008245654A (ja) | 2008-10-16 |
| JP2010166922A (ja) | 2010-08-05 |
| EP1724588A2 (de) | 2006-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE526041T1 (de) | Verfahren zur hemmung okularer vorgänge | |
| ATE310955T1 (de) | Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten | |
| DE60224383D1 (de) | Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen | |
| DE60228160D1 (de) | System und Verfahren zum Durchführen von drahtlosen Transaktionen | |
| DE60133982D1 (de) | Biosensor und verfahren zum analysieren von blutkomponenten | |
| ATA8612001A (de) | Verfahren zum testen von software | |
| DE60016178D1 (de) | Verfahren zur diagnose und zur charakterisierung von schlaganfall | |
| ATE347698T1 (de) | Verfahren zum nachweis von alzheimer-krankheit | |
| ATE447174T1 (de) | Verfahren zum direkten nachweis einzelner methotrexatmetabolite | |
| DE602004022124D1 (de) | Verfahren und Anordung zur Begutachtung der Qualität von maschineller Übersetzung | |
| ATE540319T1 (de) | Verfahren für die bestimmung von fk506 | |
| DE60235211D1 (de) | Verfahren zum Vorlöschen von Rauschen eines Bildes. | |
| DE60321356D1 (de) | Verfahren zur diagnostik von eierstock endometriose | |
| DE60322848D1 (de) | System für kontinuierliche leistungstests | |
| ATA1242002A (de) | Verfahren und einrichtung zum optischen testen von halbleiterbauelementen | |
| DE60231607D1 (de) | Zusammensetzungen und verfahren zum nachweis von ehrlichia canis- und ehrlichia chaffeensis-antikörpern | |
| ATE393394T1 (de) | Verfahren zum nachweis von proteinen, die miteinander interagieren | |
| ATE306659T1 (de) | Küvette für ein lesegerät zur bestimmung von substanzen mittels der evaneszenzfeldmethode | |
| DE502004012314D1 (de) | Verfahren zum reaktiv-färben von leder, sowie farbstoffe und deren verwendung | |
| DE50208871D1 (de) | Verfahren und filteranlage zum abscheiden von kondensat und dergleichen | |
| ATE408832T1 (de) | Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper | |
| EP1448056A4 (de) | Surfactant-protein d für die vorbeugung und diagnose von lungenemphysem | |
| DE602004030819D1 (de) | Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs | |
| DE60239364D1 (de) | Prozessor zum Umwandeln von Informationssignalen und entsprechendes Verfahren | |
| DE50115563D1 (de) | Verfahren zum Verschleifen von Maschen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |